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Peripheral peptidolgycan (PGN) is present within
antigen-presenting cells in the central nervous
system (CNS) of multiple sclerosis (MS) patients,
possibly playing a role in neuroinflammation.
Accordingly, PGN is linked with disease progression
in the animal model ofMS, experimental autoimmune
encephalomyelitis (EAE), but the role of specific
PGN-sensing proteins is unknown. Here we report
that the progression of EAE was dependent on the
intracellular PGN sensors NOD1 and NOD2 and their
common downstream adaptor molecule, receptor
interacting protein 2 (RIP2; also known as RIPK2
and RICK). We found that RIP2, but not toll-like
receptor 2 (TLR2), played a critical role in the activa-
tion of CNS-infiltrating dendritic cells. Our results
suggest that PGN in the CNS is involved in the path-
ogenesis of EAE through the activation of infiltrating
dendritic cells via NOD1-, NOD2-, and RIP2-medi-
ated pathways.
INTRODUCTION
Multiple sclerosis (MS) affects more than 2.1 million people
worldwide and is the leading cause of neurological disability in
young adults (McFarland and Martin, 2007). MS is an inflamma-
tory, demyelinating disease in which autoimmune T cells are
directed against antigens that are derived from the central
nervous system (CNS) (Sospedra and Martin, 2005). However,
myelin-reactive T cells have been found in healthy individuals,
suggesting that other factors play an important role in initiation
and perpetuation of disease progression (Compston and Coles,
2002). Bacterial and viral infections are potential cofactors impli-
cated in the initiation and persistence of autoimmune diseases
(Wucherpfennig, 2001). Accordingly, MS relapses and their
severity are frequently associated with antecedent viral and
bacterial infections (Buljevac et al., 2002, 2003; Sibley et al.,
1985).
The mechanisms underlying MS have been widely studied via
the animal model experimental autoimmune encephalomyelitis(EAE). EAE is induced in mice by immunization with myelin oligo-
dendrocyte glycoprotein (MOG) peptide in complete Freund’s
adjuvant (CFA) containing heat-killed M. tuberculosis (Stromnes
and Goverman, 2006a). It is believed that genetically predis-
posed individuals develop MS after an environmental trigger
that activates myelin-specific T cells. The initial activation
allows the T cells to cross the blood-brain barrier, but once in
the CNS the T cells must be reactivated by antigen-presenting
cells (APCs) (Goverman, 2009). The presence of peptidoglycan
(PGN)-containing APCs was detected in the brains of multiple
sclerosis patients, but not in healthy controls during a post-
mortem analysis (Schrijver et al., 2001). Additionally, PGN-con-
taining APCs were detected and localized to CNS lesions in
both nonhuman primate (Visser et al., 2006) and mouse (Visser
et al., 2005) models of MS, but were not detected in healthy
control animals. Furthermore, EAE can be induced in mice
when the bacterial cell wall component, PGN, is used as the
adjuvant in place of CFA (Visser et al., 2005). Therefore, the pres-
ence of PGN in the inflamed brain appears to play a role in the
progression of EAE, especially considering the association
between bacterial infection and MS (Buljevac et al., 2003).
However, the role of PGN-activated signaling pathways in EAE
progression has not been explored.
Recognition of PGN by both extracellular and intracellular
pattern recognition receptors induces innate immune responses.
The transmembrane protein toll-like receptor 2 (TLR2) can be
activated by PGN (Dziarski and Gupta, 2005). TLR2 has been
reported to play a role in the progression of EAE; however, the
mechanism reported was independent of PGN (Farez et al.,
2009). Additionally, members of the Nod-like receptor (NLR)
family, NOD1 and NOD2, detect PGN fragments in the cytosol
(Chamaillard et al., 2003; Girardin et al., 2003). Activation of
NOD1 and NOD2 initiates a proinflammatory signaling cascade
dependent on the recruitment of their common adaptor protein,
receptor-interacting protein 2 (RIP2; also known as RIPK2 and
RICK) and NF-kB activation (Inohara et al., 2000; Park et al.,
2007). Furthermore, RIPK2 was one of a small number of genes
that was upregulated in non-T cell fractions of the peripheral
blood of MS patients (Satoh et al., 2005). However, the role of
NOD1, NOD2, or RIP2 in EAE disease progression has not been
determined.
In this study, we demonstrate that TLR2, NOD1, NOD2, and
RIP2 play a critical role in the progression of EAE. The develop-
ment and proliferation of MOG-specific T cells in lymphoidImmunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc. 75
Figure 1. NOD1-, NOD2-, RIP2-, and TLR2-
Deficient Mice Are Resistant to EAE
Progression
(A–D) Clinical scores of wild-type (WT) mice
(n = 13–20) and (A) Nod1/ (n = 8), (B) Nod2/
(n = 15), (C) Ripk2/ (n = 21), and (D) Tlr2/
(n = 16) mice were determined daily after immuni-
zation with MOG (35-55) peptide in CFA. Data are
representative of two independent experiments.
(E) Clinical scores ofWT (n = 8) andRipk2/ (n = 9)
mice were determined daily after immunization
withMOG (35-55) peptide in IFA and soluble pepti-
doglycan.
Data were analyzed with two-way ANOVAs (mean
and SEM).
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RIP2 in CNS-Infiltrating APCs Is Critical for EAEorgans was not reduced in any of the gene-targeted mice, but
the number of T cells in the CNS was reduced in Nod1/,
Nod2/, and RIP2-deficient (Ripk2/) mice. Additionally, the
number of activated dendritic cells in the CNS after MOG-
induced EAE was greatly reduced in Nod1/, Nod2/, and
Ripk2/ mice, but not Tlr2/ mice. This decrease in CNS-infil-
trating APC activation resulted in a functional defect in the ability
of APCs to drive the differentiation of naive MOG 35-55-specific
TCR (2D2) T cells into T helper 17 (Th17) effector cells. Further-
more, WT mice reconstituted with Ripk2/ bone marrow were
resistant to EAE. This suggests that RIP2 plays a role in EAE
progression, which is intrinsic to T cells or peripheral antigen-
presenting cells. However, the adoptive transfer of MOG-
specific Ripk2/ T cells caused disease progression to a similar
degree as MOG-specific WT T cells, eliminating the possibility of
a T cell-intrinsic role for RIP2 in EAE progression. These findings
suggest a mechanistic pathway by which antigen-presenting
cells that infiltrate the CNS are activated by intracellular PGN
through NOD1 and NOD2, and in turn RIP2, leading to neuroin-
flammation and the reactivation and expansion of MOG-specific
T cells to drive EAE pathogenesis.76 Immunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc.RESULTS
Nod1–/–, Nod2–/–, and Ripk2–/– Mice
Are Highly Resistant to EAE
To study the potential role of PGN-
sensing pattern recognition receptors in
the progression of EAE, we compared
the susceptibility and severity of WT,
Nod1/, Nod2/, Ripk2/, and Tlr2/
mice to EAE induction. When immunized
by subcutaneous injection of a MOG
peptide emulsified in complete Freund’s
adjuvant and accompanied by pertussis
toxin, WT mice developed disease as
characterized by increasing paralysis.
Notably, Nod1/, Nod2/, and
Ripk2/ mice were protected from the
progression of EAE as measured by clin-
ical scores (Figures 1A–1C). Additionally,
Tlr2/ mice were resistant to EAE (Fig-
ure 1D), as reported previously (Farez
et al., 2009). The incidence of diseaseafter EAE induction was similar between WT and the gene-defi-
cient mice; however, the severity of disease progression was
dampened in all groups of gene-deficient mice (Table 1). The
percent of mice that developed hind-limb paralysis after EAE
immunization was reduced in all gene-deficient mice (Table 1).
However, protection fromdisease progressionwasmore consis-
tent in Ripk2/ mice when compared to Nod1/ or Nod2/
mice. Additionally, the day of onset was slightly delayed in
Nod1/, Nod2/, and Ripk2/mice. Interestingly, the Tlr2/
mice actually had a quicker onset of disease despite being pro-
tected fromdisease later in the time course. This finding is similar
to previously reported EAE clinical scores in Tlr2/ mice (Farez
et al., 2009; Prinz et al., 2006). Histological analysis of spinal cord
sections also showed thatWTmice developed prominent inflam-
matory infiltration and axon demyelination (Figure 2). In contrast,
Nod1/,Nod2/, andRipk2/mice had decreased inflamma-
tory infiltrate and decreased axon demyelination. Tlr2/ mice
exhibited similar inflammatory infiltration compared to WT mice
but had decreased axon demyelination.
To determine whether the protection from EAE observed in
Ripk2/ mice was PGN dependent, mice were immunized
Table 1. EAE Progression in Wild-Type, Nod1–/–, Nod2–/–, Ripk2–/–, and Tlr2–/– Mice
Mouse Genotype Incidence
Day of Onset
(Mean ± SEM)
Developed Complete
Hind-Limb Paralysis (%)
Maximum Clinical Score
(Mean ± SEM)
Wild-type 50/51 (98.03%) 14.10 ± 0.31 95 2.83 ± 0.24
Nod1/ 8/8 (100%) 16.75 ± 0.86 50 1.31 ± 0.25
Nod2/ 15/15 (100%) 16.20 ± 0.69 40 1.57 ± 0.19
Ripk2/ 15/16 (93.75%) 17.67 ± 1.19 19 1.41 ± 0.23
Tlr2/ 22/22 (100%) 11.68 ± 0.36 55 2.23 ± 0.17
Results are cumulative data from six different experiments.
Immunity
RIP2 in CNS-Infiltrating APCs Is Critical for EAEwith MOG peptide and incomplete Freund’s adjuvant containing
soluble PGN. Ripk2/ mice were protected from disease
progression after PGN EAE immunization when compared to
WT mice (Figure 1E). These results indicate a critical, PGN-
dependent role for NOD1, NOD2, and RIP2 in EAE pathogenesis.
Therefore, we further characterized disease progression to iden-
tify a potential mechanism by which NOD1, NOD2, and RIP2
contribute to autoimmunity.
NOD1, NOD2, and RIP2 Are Not Required for
MOG-Specific T Cell Development and Proliferation
To investigate whether NOD1, NOD2, RIP2, and TLR2 contribute
to the priming, differentiation, and proliferation of MOG-specific
T cells, we assessed the number and proliferative capacity
of MOG-specific T cells in the peripheral lymphoid organs
10 days after immunization. Splenocytes were incubated with
various concentrations of MOG peptide for 48 hr, with [H3]thymi-
dine added for the final 8 hr and its incorporationmeasured. At all
concentrations of MOG peptide, the proliferation of MOG-
specific T cells was similar between WT and gene-deficient
mice (Figure 3A). In addition, we quantified the number of
MOG-specific T cells in the draining lymph nodes by stimulating
T cells with MOG peptide for 5 hr in the presence of monensin
and staining for intracellular cytokines. There was not a differ-
ence in the number of Th1 or Th17 MOG-specific T cells in
Nod1/, Nod2/, or Ripk2/ mice (Figure 3B). In contrast,
Tlr2/ mice had substantially more Th1 MOG-specific T cells,
which suggests a distinct role for TLR2 in Th1 and Th17 cells,
as recently reported (Reynolds et al., 2010), and might explain
the earlier disease onset. Nevertheless, our results demonstrate
that the resistance to EAE in Nod1/, Nod2/, and Ripk2/
mice is not due to a defect in MOG-specific T cell development
and expansion.
Reduced T Cell Accumulation in the CNS
of Ripk2–/– Mice
Lymphocytes were isolated from the CNS of mice, and the total
number of T cells and MOG-specific T cells were quantified.
The number of CNS-infiltrating CD4+ T cells in untreated WT
and Ripk2/ mice is equivalent (Figure S1A available online).
However, 17 days after EAE immunization, there was a trend
toward a reduction in total CD4+ T cells in Nod1/ and Nod2/
mice, andRipk2/mice had a significant (p = 0.025) reduction in
the total number of CD4+ T cells in the CNS (Figure 4A). This
finding was confirmed with CD3+ T cell immunohistochemistry
of spinal cords (Figure 4B). Nod1/, Nod2/, and Ripk2/
mice had a drastic reduction in positively stained T cells presentin the spinal cord compared to WT mice. To determine whether
this finding was also reflected in disease-specific T cells,
lymphocytes were cultured with MOG peptide for 5 hr in the
presence of monensin and stained for intracellular cytokines.
Ripk2/ mice had significantly less Th1 (p = 0.031) and Th17
(p = 0.048) MOG-specific CD4+ T cells in the CNS (Figure 4C).
Tlr2/ mice had similar numbers of MOG-specific T cells as
did WT mice. The results collectively indicate that RIP2 is
involved in a mechanism that affects the CNS accumulation of
all T cells and is not specific to Th1 or Th17 cells. However, at
an early time point (5 days after EAE immunization), WT and
Ripk2/ mice had equivalent numbers of CNS-infiltrating
CD4+ T cells (Figure S1B). Therefore, we conclude that the
decrease in CD4+ T cells in the CNS of Ripk2/ mice at a later
time point during EAE is not due to a defect in the ability of
lymphocytes to migrate into the CNS.
The Number of Activated APCs in the CNS Is Reduced
in Nod1–/–, Nod2–/–, and Ripk2–/– Mice
The progression of EAE is dependent on the reactivation of
T cells within the CNS by dendritic cells. In untreated mice,
the number of CD11c+ cells is equivalent in WT and Ripk2/
mice (Figure S1A). After EAE induction, cells isolated from the
CNS were analyzed for the number and activation status of
dendritic cells. The total number of CD11c+ cells in the CNS
17 days after EAE immunization was reduced in Nod1/ and
Nod2/ mice and to an even greater degree in Ripk2/ mice
(Figure 5A). Of the CNS-infiltrating APCs during EAE, myeloid
dendritic cells (mDCs) are the most abundant and critically
important to disease progression among the various APC
subsets (Bailey et al., 2007; Miller et al., 2007). The CNS infiltra-
tion of mDCs was drastically reduced in Ripk2/ mice (Fig-
ure 5B). Additionally, the total number of CD8+ DCs and macro-
phages in the CNS was reduced in Ripk2/ mice 17 days after
EAE induction.
To test whether the decrease in CD11c+ cells present in the
CNSofRipk2/mice is an intrinsic defect in dendritic cell migra-
tion, we tested the migratory ability of bone-marrow-derived
dendritic cells (BMDCs) to chemokine in vitro. Ripk2/ BMDCs
were able to migrate across a transwell to the chemokine
gradient to the same degree as WT BMDCs (Figure S2A). Addi-
tionally, we analyzed the infiltration of dendritic cells, macro-
phages, and granulocytes into the CNS 5 days after immuniza-
tion. At this early time point, WT and Ripk2/ mice have
equivalent numbers of CNS-infiltrating dendritic cells, macro-
phages, and granulocytes (Figure S1B). Therefore, we conclude
that the decrease in CD11c+ cells present in the CNS ofImmunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc. 77
Figure 2. Regulation of EAE Development by NOD1, NOD2, RIP2,
and TLR2
Histology of paraffin sections of spinal cords isolated from WT, Nod1/,
Nod2/, Ripk2/, and Tlr2/ mice (n = 4 per group) on day 17 after immu-
nization. Images are representative of the group. H&E, hematoxylin and eosin;
LFB, Luxol fast blue.
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RIP2 in CNS-Infiltrating APCs Is Critical for EAERipk2/ mice at day 17 during EAE is not due to an intrinsic
defect in dendritic cell migration.
We next determinedwhether the activation state and function-
ality of CNS-infiltrating DCs is affected by NOD1, NOD2, or RIP2
deficiency. CNS-infiltrating DCs express Nod1, Nod2, and
Ripk2, with the expression of Nod2 being slightly higher than
that of Nod1 (Figure S2B). However, we found that the percent
of activated CD11c+ cells, as determined by high MHC II surface
expression, was decreased only in Ripk2/ mice (Figure 5C).
The percent of activated CD11c+ cells was slightly decreased
in mice deficient in NOD1 or NOD2 alone, but not to a significant
degree (p = 0.18, 0.13; respectively). Only in Ripk2/ mice,78 Immunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc.equivalent to the removal of both NOD1 and NOD2, is there
a significant decrease in CD11c+ activation (p = 0.017). However,
the total number of activated CD11c+ cells in the CNS was
reduced in Nod1/ and Nod2/ mice and to an even greater
degree in Ripk2/ mice (Figure 5D). In contrast, Tlr2/ mice
had similar CD11c+ cell numbers and activation levels as did
WT mice.
The functional ability of APCs isolated from WT and Ripk2/
spinal cords during EAE progression was examined by culturing
the isolated APCs with naive 2D2 TCR T cells as described previ-
ously (Bailey et al., 2007). CNS-infiltrating APCs from WT and
Ripk2/ mice induced the proliferation of naive 2D2 T cells to
a similar degree (data not shown). However, CNS-infiltrating
APCs from Ripk2/ mice were impaired in their ability to drive
the differentiation of naive 2D2 T cells into Th17 effector cells,
as measured by cytokine release (Figure 5E). Overall, these
results suggest that NOD1 and NOD2 have redundant roles in
CNS-infiltrating dendritic cell activation during EAE. Additionally,
RIP2 signaling is critical to CNS-infiltrating dendritic cell activa-
tion and, in turn, the ability of these APCs to drive the differenti-
ation of CNS-infiltrating T cells into functional Th17 effector cells,
which are required for the progression of EAE and MS.
Resistance to EAE in Ripk2–/– Mice Is Intrinsic
to CNS-Infiltrating Dendritic Cell Activation
To further examine the particular cell type that requires RIP2
activity for EAE progression, we created Ripk2/ and WT
bone marrow chimeras. As a positive control, Ripk2/ host
mice transplanted with Ripk2/ bone marrow (Ripk2/ /
Ripk2/) were resistant to MOG-induced EAE (Figure 6A). Irra-
diated WT mice transplanted with Ripk2/ bone marrow
(Ripk2/ / WT) were also resistant to EAE, whereas host
Ripk2/ mice transplanted with WT bone marrow developed
EAE progression similar to WT mice. This result indicates that
RIP2 in the hematopoietic cell population plays a critical role in
the development of EAE. Cell populations within the CNS were
analyzed 15 days after immunization. Both Ripk2/ / WT
and Ripk2/ / Ripk2/ mice had fewer CD4+ T cells and
a trend toward fewer CD11c+ cells compared to WT / WT
mice (Figure 6B).
Ripk2/ / WT mice, resistant to EAE progression, have
Ripk2/ peripheral dendritic cells and Ripk2/ T cells. There-
fore, to determine which cell population requires RIP2 signaling
for EAE progression, we passively induced EAE via an adoptive
transfer of MOG-specific T cells into naive WT mice (Stromnes
and Goverman, 2006b). The adoptive transfer of MOG-specific
Ripk2/ T cells induced disease progression to the same
degree as did WT T cells (Figure 6C). This suggests that EAE
progression is not dependent on RIP2 activation in T cells.
Collectively with the bone marrow chimera results, these results
suggest that EAE progression is dependent on RIP2 activation in
peripheral antigen-presenting cells.
Using congenically markedmice for bonemarrow chimeras al-
lowed for us to distinguish infiltrating peripheral dendritic cells
from CNS-resident microglia. Microglia are irradiation resistant
and only a small fraction are replaced by injected bone marrow
in irradiated mice (Flugel et al., 2001; Priller et al., 2001). The acti-
vation of infiltrating dendritic cells is dependent on RIP2 (Fig-
ure 6D, top). Additionally, microglia activation is dependent on
Figure 3. NOD1, NOD2, RIP2, and TLR2 Are Not Required for MOG-Specific T Cell Development and Proliferation
(A) Quantification of the proliferation of MOG-specific T cells isolated from the spleens of mice 10 days after immunization (n = 7–8).
(B) Absolute number of MOG-specific CD4+IFN-g+ (Th1), CD4+TNF-a+ (Th1), and CD4+IL-17+ (Th17) T cells in the draining lymph node 10 days after immunization
(n = 8). *p < 0.05 and **p < 0.005, versus WT (Student’s t test).
Data are representative of two independent experiments (mean and SEM).
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RIP2 in CNS-Infiltrating APCs Is Critical for EAERIP2 (Figure 6D, bottom). Bothmicroglia and infiltrating dendritic
cells are activated through a RIP2-mediated pathway, but the
majority of CD11c+ cells in the CNS during EAE are peripheral
dendritic cells, explaining why only Ripk2/ / WT mice are
resistant to EAE. Collectively, these results indicate that the acti-
vation of CNS-infiltrating peripheral dendritic cells is dependent
on RIP2, a mechanism probably responsible for the resistance to
EAE of Ripk2/ mice.
DISCUSSION
Antigen-presenting cells (APCs) within the CNS of patients with
multiple sclerosis contain PGN, which could potentially stimulate
innate immune responses and contribute to CNS autoimmune
disease progression in the absence of bacterial replication in
the brain (Schrijver et al., 2001). In this study we have investi-
gated the function of cytosolic PGN sensors NOD1 and NOD2,
in addition to their common downstream adaptor protein,
RIP2, in the progression of EAE.
We have shown here that Nod1/, Nod2/, and Ripk2/
mice were highly resistant to EAE in a PGN-dependent manner,
with Ripk2/ mice showing the greatest degree of protection.
This protection occurs despite normal development of MOG-
specific Th1 and Th17 cell responses in the periphery. Recent
studies identified a T cell-intrinsic role for NOD2 in Th1 cell differ-
entiation during Toxoplasma gondii infection (Shaw et al., 2009).
However, NOD1, NOD2, and RIP2 do not play a role in Th1 orTh17 cell differentiation during EAE, as indicated by the fact
that the development of MOG-specific IFN-g+, TNF-a+, and
IL-17+CD4+ T cells in the lymph node was similar to WT mice.
T cell responseshavebeenshownbyseveral reports tobenormal
inRipk2/mice (Fairhead et al., 2008; Hall et al., 2008; Nembrini
et al., 2008), but it has been suggested that RIP2 is involved in
theCD40signalingpathway,which is critical to EAEdevelopment
(Du et al., 2009). However, Ripk2/mice did show signs of EAE
pathogenesis, although to a lesser degree than WT, and had
normal MOG-specific T cell development; both of which are in
contrast to Cd40/mice (Becher et al., 2001).
In contrast to the periphery, there was a decrease in the total
number of MOG-specific Th1 and Th17 cells in Ripk2/mice in
the CNS at day 17 during EAE. However, the accumulation of
T cells in the CNS during EAE in Ripk2/ mice was normal at
an early time point (day 5). Furthermore, the adoptive transfer
of MOG-specific Ripk2/ T cells induced disease progression
to a similar degree as did WT T cells. This suggests that RIP2
does not play a role in EAE progression intrinsic to T cell function.
Additionally, the reduced accumulation of T cells in the CNS at
day 17 in Ripk2/ mice is not intrinsic to T cell migration, but
rather the difference in the CNS accumulation of T cells at day
17 is intrinsic to dendritic cells via reduced reactivation and
expansion of T cells in the CNS during EAE.
Similar to CD4+ T cell accumulation, in Ripk2/mice the total
number of CNS-infiltrating dendritic cells was drastically
reduced at day 17 during EAE progression, but was not differentImmunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc. 79
WT Nod1-/- 
Nod2
-/- Tlr2
-/- 
Ripk2
-/- 
A 
C 
N
um
be
r o
f c
el
ls
 
(x
 1
03
) 
B UT 
U
nt
re
at
ed
 
W
T 
N
o
d
1
-
/
-
 
N
o
d
2
-
/
-
 
R
ip
k
2
-
/
-
 
T
lr
2
-
/
-
 
N
um
be
r o
f c
el
ls
 
(x
 1
02
) 
U
nt
re
at
ed
 
W
T 
N
o
d
1
-
/
-
 
N
o
d
2
-
/
-
 
R
ip
k
2
-
/
-
 
T
lr
2
-
/
-
 
U
nt
re
at
ed
 
W
T 
N
o
d
1
-
/
-
 
N
o
d
2
-
/
-
 
R
ip
k
2
-
/
-
 
T
lr
2
-
/
-
 
U
nt
re
at
ed
 
W
T 
N
o
d
1
-
/
-
 
N
o
d
2
-
/
-
 
R
ip
k
2
-
/
-
 
T
lr
2
-
/
-
 
Figure 4. CNS Accumulation of T Cells during EAE Is Dependent on RIP2
(A) Quantification of CD4+ T cells in mononuclear cell infiltrates isolated from spinal cords of mice 17 days after immunization (n = 8).
(B) CD3 T cell histology staining of paraffin sections of spinal cords isolated from untreated (UT) mice and mice 17 days after immunization (n = 4). Images are
representative of the group.
(C) Absolute numbers of MOG-specific CD4+IFN-g+ (Th1), CD4+TNF-a+ (Th1), and CD4+IL-17+ (Th17) T cells in the spinal cord 17 days after immunization (n = 8).
*p < 0.05, **p < 0.005, and ***p < 0.001, versusWT (Student’s t test). Data are representative of two independent experiments (mean and SEM). See also Figure S1.
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RIP2 in CNS-Infiltrating APCs Is Critical for EAEfrom WT mice at an early time point (day 5). This, in addition
to the normal migration of RIP2-deficient BMDCs, suggests
that the RIP2 signaling pathway is not involved in the initial migra-
tion of CD11c+ cells into the CNS during EAE. Rather, the reac-
tivation of APCs within the CNS could result in decreases in the
accumulation of inflammatory cells during EAE via reduced
neuroinflammation and lymphocyte reactivation within the
CNS. The percent of CD11c+ cells activated within the CNS
during EAE was substantially reduced in Ripk2/ mice. NOD1
and NOD2 probably have some redundancy in their role during
EAE progression, because Nod1/ and Nod2/ mice were
both resistant to EAE progression. However, the protection
from EAE in eitherNod1/ orNod2/mice was less consistent
than in Ripk2/ mice. Additionally, NOD1 or NOD2 deficiency
resulted in a trend toward reduced dendritic cell activation in
the CNS, whereas mice deficient in RIP2, the common down-
stream adaptor of NOD1 and NOD2, exhibited a greater, signif-
icant reduction in dendritic cell activation. However, both
Nod1/ and Nod2/ mice were resistant to EAE, in contrast
to a report in an arthritis model where Nod1/ and Nod2/
mice had opposite phenotypes (Joosten et al., 2008). NOD1
and NOD2 have some redundant role in the activation of
dendritic cells within the CNS, but both receptors appear to be
dependent on RIP2 for this function.80 Immunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc.InNod1/,Nod2/, andRipk2/mice, CD11c+ activation in
the periphery was normal, whereas activation was decreased in
the CNS. This is probably due to the very different microenviron-
ments in which the CD11c+ cells are present. CD11c+ cells in the
periphery are exposed to a plethora of activating ligands, with
the most important probably being extracellular TLR ligands,
as evidenced by the inability of MyD88/ mice to develop
EAE (Prinz et al., 2006). Therefore, peripheral Ripk2/ APCs
are activated to the same degree as WT mice, as indicated by
the fact that there are several stimuli present that act indepen-
dently of RIP2 to activate APCs. In the periphery, dendritic cells
phagocytose PGN from either the intestinal microbiota or the
CFA in the case of EAE induction (Visser et al., 2005). Once the
APCs migrate to within the CNS, extracellular stimuli that can
activate APCs are probably less abundant because of the
blood-brain barrier. Therefore, once APCs migrate to the CNS,
they become critically dependent on ‘‘self-activation’’ by sensing
the intracellular PGN that they have carried into the CNS. Activa-
tion of CNS-infiltrating APCs in Tlr2/ mice were not reduced,
suggesting that the mechanisms underlying resistance to EAE
in Ripk2/ and Tlr2/ mice are different, and therefore inhibi-
tion of both RIP2 and TLR2 signaling would probably have an
additive effect of protection from EAE. However, the recognition
of intracellular PGN, and its inflammatory effect, is dependent on
Figure 5. Accumulation and Activation of CD11c+ Cells within the CNS during EAE Is Dependent on RIP2
(A and B) Quantification of (A) CD11c+ cells and (B) APC subsets in mononuclear cell infiltrates isolated from spinal cords of mice 17 days after immunization
(n = 5–8).
(C) Percentage activated of the CD11c+ cell population measured by high MHC II surface expression (n = 8).
(D) Absolute number of activated CD11c+ cells in mononuclear cell infiltrates isolated from spinal cords of mice 17 days after immunization (n = 8).
(E) CD11c+ cells were isolated from the spinal cords ofWT andRipk2/mice on day 17 of EAE disease progression. Isolated APCswere pooled and culturedwith
naive 2D2 TCR T cells (10:1 T cell:APC ratio) for 72 hr. Supernatants were collected and IFN-g and IL-17 was measured (n = 11–14).
*p < 0.05, **p < 0.005, and ***p < 0.001, versusWT (Student’s t test). Data are representative of two independent experiments (mean and SEM). See also Figure S2.
Immunity
RIP2 in CNS-Infiltrating APCs Is Critical for EAEthe NOD1-NOD2-RIP2 signaling pathway; therefore, CNS-infil-
trating APCs deficient in the RIP2 signaling axis are unable to
activate and expand.
Peripherally derived myeloid dendritic cells present myelin
antigens to preactivated myelin-specific T cells and naiveT cells more efficiently than CNS-resident APCs, microglia (Miller
et al., 2007). APCs isolated from the CNS of Ripk2/mice were
functionally defective in driving the differentiation of naive 2D2
T cells into effector Th17 cells. Therefore, reduced activation of
APCs within the CNS resulted in decreased T cell reactivationImmunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc. 81
Figure 6. RIP2 Signaling Is Critical for EAE Progression via CNS-Infiltrating Dendritic Activation
(A) Clinical scores of EAE progression in WT/RIP2 bone marrow chimeric mice (n = 13). Data are representative of two independent experiments.
(B) Absolute numbers of CD4+ T cells and CD11c+ cells in monocuclear cell infiltrates isolated from spinal cords of mice 15 days after immunization (n = 5).
(C) Clinical scores of EAE progression after the adoptive transfer of MOG-specific Ripk2/ or WT T cells into naive WT mice (n = 10).
(D) Quantification of peripherally derived dendritic cell and microglia populations, distinguished via congenic surface markers (n = 5).
Data were analyzed via a two-way ANOVA (A and C) or Student’s t test (B and D). *p < 0.05, **p < 0.005, and ***p < 0.001, versus WT (Student’s t test; B and D).
(Mean and SEM.)
Immunity
RIP2 in CNS-Infiltrating APCs Is Critical for EAEand ameliorated EAE progression. Nevertheless, to differentiate
the role of RIP2 signaling in peripherally derived dendritic cells
andmicroglia in the CNS during EAE,WT-Ripk2/ bonemarrow
chimeras were created. Microglia are irradiation resistant and82 Immunity 34, 75–84, January 28, 2011 ª2011 Elsevier Inc.only a small fraction of these cells are readily replenished after
bone marrow transplantation (Flugel et al., 2001; Priller et al.,
2001). Therefore, microglia and peripherally derived dendritic
cells can be distinguished. The activation of both microglia and
Immunity
RIP2 in CNS-Infiltrating APCs Is Critical for EAEperipherally derived dendritic cells was dependent on RIP2.
However, microglia are inefficient in myelin-specific antigen
presentation and peripherally derived dendritic cells make up
the majority of CD11c+ cells in the CNS during EAE. Therefore,
only chimeric mice with Ripk2/ infiltrating dendritic cells are
resistant to EAE.
In summary, our observations have provided a mechanistic
link by which PGN present in the brain of MS patients could
contribute to disease progression. Our results suggest that acti-
vation of CNS-infiltrating dendritic cells by PGN is dependent on
NOD1- and NOD2-mediated RIP2 activation. The RIP2 signaling
pathwaywas not involved in themigration of T cells and dendritic
cells into the CNS during EAE, but rather played a critical role in
the self-activation of CNS-infiltrating dendritic cells. This self-
activation of APCs is essential for EAE progression through the
reactivation and expansion of MOG-specific T cells. Accord-
ingly, CNS-infiltrating CD11c+ cells isolated from Ripk2/
mice after EAE immunization were functionally impaired in their
ability to drive Th17 cell responses compared to their WT coun-
terpart. Furthermore, RIP2 played a role in the progression, not
the initiation, of EAE; therefore, RIP2 inhibition might prove
therapeutically useful for the alleviation of ongoing disease by
preventing T cell reactivation in the CNS. Importantly, RIP2
inhibition would target the dendritic cell component of MS
progression, whereas most current MS therapies target the
T cell component. Therefore, RIP2 inhibition could provide an
additive or synergistic therapeutic effect when used in conjunc-
tion with current MS treatment strategies. Overall, inhibition of
RIP2 activation in CNS-infiltrating dendritic cells represents
a unique and valuable therapeutic strategy for multiple sclerosis.EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from Jackson Laboratory. The generation of
Nod1/, Nod2/, Ripk2/, and Tlr2/mice has been described previously
(Chamaillard et al., 2003; Kobayashi et al., 2002, 2005; Wooten et al., 2002)
and the mice backcrossed onto a C57BL/6 background for at least ten gener-
ations. Mice were housed in a pathogen-free facility and the animal studies
were conducted under protocols approved by St. Jude Children’s Research
Hospital Committee on Use and Care of Animals.EAE Model
Female mice 7–9 weeks of age were immunized subcutaneously with 100 mg
MOG (35-55) peptide (MEVGWYRSPFSRVVHLYRNGK) emulsified in CFA or
incomplete Freund’s adjuvant with soluble PGN (25 mg total per mouse) on
day 0. Pertussis toxin (200 ng; List Biological Laboratories, Inc.) was injected
intraperitoneally on days 0 and 2 (Stromnes and Goverman, 2006a; Visser
et al., 2005). EAE was induced by the adoptive transfer of MOG-specific
T cells as described previously (Stromnes and Goverman, 2006b). In brief,
splenocytes were collected frommice 10 days after immunization and cultured
for 72 hr in the presence of MOG peptide. 153 106 T cells were injected intra-
venously to sublethally irradiated (400 rad) naive WT mice. Pertussis toxin was
injected intraperitoneally on days 0 and 2. Disease severity was assessed daily
by assigning scores on the following scale: 0, no disease; 1, tail paralysis; 2,
weakness of hind limbs; 3, paralysis of hind limbs; 4, paralysis of hind limbs
and severe hunched posture; 5, moribund or death. CNS lymphocytes were
collected as described previously (Ivanov et al., 2007). In brief, mice were
perfused through the left ventricle with ice-cold 2 mMEDTA in PBS. The spinal
cord was dissected, cut into small pieces, and digested in collagenase D
(1 mg/mL; Roche Diagnostics) for 45 min at 37C. Spinal cord sections were
passed through a 70 mm cell strainer, washed once in PBS, placed in a 38%Percoll solution, and pelleted for 20 min at 2000 rpm. Pellets were resus-
pended in media and used for subsequent studies and analysis.
MOG-Specific T Cell Proliferation
Cells were harvested from the spleen 10 days after immunization. 23 105 cells
were plated in triplicate in a 96-well plate with various concentrations of MOG
peptide and incubated at 37C for 48 hr. [3H]thymidine was added for the last
8 hr of culture, and the amount of incorporated [3H]thymidine was measured.
Flow Cytometry and In Vitro Stimulation
For the analysis of mouse phenotypes, the following monoclonal antibodies
were used: CD4 (L3T4), IFN-g (XMG1.2), IL-17A (eBio17B7), MHC II (M5/
114.15.2), CD11b (M1/70), PDCA-1 (eBio927), B220 (RA3-6B2), and Gr-1
(RB6-8C5) from eBioscience and TCR-b (H57-597), TNF-a (MP6-XT22),
CD11c (N418), CD45.1 (A20), and CD45.2 (104) from Biolegend. For intracel-
lular cytokine staining, cells were stimulated for 4.5 hr with 30 mg/mL
MOG peptide, with the final 2 hr of culture in the presence of monensin
(eBioscience). After surface staining, cells were permeabilized with permeabi-
lization wash buffer (Biolegend) and stained for intracellular cytokines.
Samples were acquired on a FACSCalibur LSR II (BD Biosciences) and
analyzed with Flowjo software (TreeStar).
Activation of 2D2 TCR T Cells by CNS-Infiltrating APCs
Infiltrating cells were isolated from spinal cords of WT and Ripk2/ mice on
day 17 after EAE immunization. Cells were pooled for each group and
CD11c+ cells were purified. Naive (CD4+CD62L+) 2D2 TCR T cells were
cultured with the isolated CNS-infiltrating APCs at a 10:1 ratio. Supernatants
were removed after 72 hr and IFN-g and IL-17 were measured with a bioplex
kit (Millipore).
Histopathology
Mice were euthanized 17 days after MOG immunization. Spinal cords were
dissected and fixed in formalin. Spinal cord sections were stained with hema-
toxylin and eosin, luxol fast blue, or polyclonal CD3. Images representative of
the group are shown.
Generation of Bone Marrow Chimeras
WT and Ripk2/ mice, lethally irradiated with a split dose of 1200 rads, were
injected with 5 3 106 bone marrow cells isolated from WT or Ripk2/ mice.
The mice were rested for 6 weeks to allow for successful engraftment. The
bone marrow transplants were validated with congenic markers (CD45.1 or
CD45.2).
Statistics
Differences between clinical score data sets were analyzed by two-way
ANOVA. Differences between all other data sets were analyzed by Student’s
t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at doi:10.1016/
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